Schisandrol B protects against cholestatic liver injury through pregnane X receptors.

ABSTRACT:

Background and purpose

Currently, ursodeoxycholic acid and obeticholic acid are the only two FDA-approved drugs for cholestatic liver diseases. Thus, new therapeutic approaches need to be developed. Here we have evaluated the anti-cholestasis effects of Schisandrol B (SolB), a bioactive compound isolated from Schisandra sphenanthera.

Experimental approach

Hepatoprotective effect of SolB against intrahepatic cholestasis, induced by lithocholic acid (LCA), was evaluated in mice. Metabolomic analysis and gene analysis were used to assess involvement of pregnane X receptor (PXR). Molecular docking, cell-based reporter gene analysis and knockout mice were used to demonstrate the critical role of the PXR pathway in the anti-cholestasis effects of SolB.

Key results

SolB prot

SUBMITTER: Zeng H 

PROVIDER: S-EPMC5368048 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature